The Developmental Therapeutics Program (DT) fosters cancer-focused inter-disciplinary research among basic scientists and clinical researchers who are focused on the discovery, development and delivery of new anti-cancer therapies. The Program Leaders promote interaction and collaboration among DT members, which stimulates breakthroughs in diagnosis, treatment and prevention of cancer.

The goal this program is to ensure that the fellows are adequately exposed to patients that are referred to phase I clinics and that they regularly see and assess patients that are on early clinical trials. Since an important part of developing an academically viable career as a clinician is to become somewhat disease-focused, fellows will be able to decide whether they would like to attend another specialty clinic with the intent of allowing the fellow to collaborate with a subspecialty clinic in designing and implementing disease-directed clinical trials with novel agents.

The Developmental Therapeutics Fellowship educates fellows to reduce the cancer burden through integration of the processes of discovery, development, and delivery of new anticancer agents.

The goal of the Thoracic Oncology Felllowship is to train oncology fellows in state‐of‐the‐art high quality care for patients with Thoracic Malignancies and in the conduct of clinical and translational research related to such patients. As novel compounds move from the laboratory to the clinic,
it is imperative that academic clinical researchers be trained in appropriate clinical trial methodology, including the use and analysis of biological correlates and have a full understanding of the drug development process.

Candidates are expected to be directly involved in the supervised care of thoracic oncology patients and to be involved with and develop clinical research protocols. Writing and submission of manuscripts for publication of clinical and translational research studies is expected during the fellowship.

This program will ensure that the fellows are adequately exposed to patients with thoracic malignancies within a world‐class multidisciplinary clinical program. By regularly seeing and assessing these patients, they will learn state‐of‐the‐art clinical management and through involvement in the conduct of clinical and translational research, the methodology for developing new treatments in the future. As most major breakthroughs in thoracic oncology occur through the use of novel pharmaceuticals, additional training experience can be provided by off‐site attachments to the pharmaceutical industry under the direct supervision of faculty associated with this program.